Invest now
Emcure Pharmaceuticals share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹1,851.25(-3.42%)October 8, 2026 15:50:00 PM IST
- NSE
- BSE
- Vol : 68.88 K (NSE + BSE)Last 20 day avg : 223.91 K
Emcure Pharmaceuticals is trading -3.42% lower at Rs 1,851.25 as compared to its last closing price. Emcure Pharmaceuticals has been trading in the price range of 1,916.75 & 1,840.90. Emcure Pharmaceuticals has given 35.69% in this year & -4.71% in the last 5 days. Emcure Pharmaceuticals has TTM P/E ratio 34.41 as compared to the sector P/E of 33.60.There are 6 analysts who have initiated coverage on Emcure Pharmaceuticals. There are 5 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 293.98 Crores in its last quarter.Listed peers of Emcure Pharmaceuticals include Sun Pharmaceutical Industries (-1.72%), Divi's Laboratories (-1.99%), Torrent Pharmaceuticals (-0.74%).The Mutual Fund holding in Emcure Pharmaceuticals was at 6.87% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Emcure Pharmaceuticals was at 4.87% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 09 Oct 2026, 07:27 AM IST
- Debt To EquityHigher than industry0.31The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.19Annual dividends as a percentage of the stock price.
- PEG RatioIndicates Fair Valuation1.79The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Emcure Pharmaceuticals News
Emcure Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,752.50 | -1.72 | 4,20,473.54 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,389.00 | -1.99 | 2,49,248.45 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,675.00 | -0.74 | 1,77,815.61 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,305.00 | -1.84 | 1,05,425.52 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,115.20 | -3.36 | 1,11,241.63 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allEmcure Pharmaceuticals Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-06 | Quarterly Results |
| 2026-05-05 | Audited Results & Final Dividend |
| 2026-02-04 | Quarterly Results |
| 2025-11-11 | Quarterly Results |
| 2025-08-07 | Quarterly Results |
About the company Emcure Pharmaceuticals
- IndustryBiotechnology & Drugs
- ISININE168P01015
- BSE Code544210
- NSE CodeEMCURE
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active Pharmaceutical Ingredient (APIs). It operates across a wide scope of areas, including Gynecology, Cardiovascular, HIV Antivirals, VMN (Vitamins, Minerals & Nutrients), Pain/Analgesics, Nephrology, Oncology, Anti-Infective, Respiratory, CNS. Its brands include Orofer XT and Pause (Gynecological), Proxym (pain), Tenectase (CNS), Vylda (diabetology), Vitanova (VMN). Its API products include S-Amlodipine, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (Tenecteplase), Vintor (Erythropoietin), TENECTASE (Tenecteplase). It has developed two platforms: Mammalian and Microbial.
Emcure Pharmaceuticals Share Price FAQs
Emcure Pharmaceuticals is trading at 1851.25 as on Thu Oct 08 2026 10:20:00. This is -3.42% lower as compared to its previous closing price of 1916.80.
The market capitalization of Emcure Pharmaceuticals is 35120.19 Cr as on Thu Oct 08 2026 10:20:00.
The average broker rating on Emcure Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 0.00 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Emcure Pharmaceuticals is 2101.00 whereas the 52 wk low is 1307.50
Emcure Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 34.41
- Sector P/E: 33.60
- Dividend Yield: 0.19%
- D/E ratio: -
Emcure Pharmaceuticals reported a net profit of 924.36 Cr in 2026.
The Mutual Fund Shareholding was 6.87% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Emcure Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.